Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Angiodynamics Inc Raises FY 2014 Guidance; Issues Q2 2014 Guidance; EPS Guidance Above Analysts' Estimates


Thursday, 10 Oct 2013 04:01pm EDT 

Angiodynamics Inc announced that for fiscal 2014, it is raising revenue expectations, following the recent distributor acquisition, to a range of $347 million to $353 million. As a result of debt refinance results, the Company is also increasing adjusted EPS without amortization to be $0.63-$0.67. For the second quarter of 2014, it expects revenue to range from $85 million to $88 million and adjusted EPS without amortization to be $0.12-$0.15. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $349 million and EPS of $0.32 for fiscal 2014; revenues of $87 million and $0.08 for the second quarter of 2014. 

Company Quote

14.15
-1.13 -7.40%
24 Jul 2014